AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Study on Treatment of Varicose Veins by Endovenous Laser (1940 nm vs 1470 nm)

RecruitingNAAges 18 Years - anyAllClinique Pasteur
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to compare efficacy of two wavelength for EndoVenous Laser Ablation (EVLA) in treatment of varicose veins of the lower limbs. The main questions it aims to answers are : 1. Is the increase of wavelength form 1470 nm to 1940 nm affect the efficacy of varicose veins treatment ? 2. Is the increase of wavelength reduce complication or pain ? Participants are patients with varicose veins of lower limbs and candidate for endovenous laser ablation. After laser ablation patients will be followed during 5 years for clinical evaluation, recording potential treatment complications and quality of life evaluation. Researchers will compare strategy 1(EVLA with an endovenous laser at 1940 nm) vs strategy 2 (EVLA with an endovenous laser at 1470 nm) in varicose veins treatment to see if efficacy of treatment is not reduce, and to see if complications of EVLA treatm

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Primary insufficiency of the great saphenous vein (GSV) and/or small saphenous vein (SSV) * Patient candidate for endothermic treatment of the lower limbs * CEAP: C2 - C6 * Patient with a target vein diameter (GSV and/or SSV) \>= 3 mm throughout the target vein segment * Patient affiliated or beneficiary of a social security scheme * Patient having signed the informed consent Exclusion Criteria: * Patient with a current serious pathology and/or a life expectancy of less than 5 years * Patient who has had a deep or superficial vein thrombosis in the previous 6 months * Obliterating arteriopathy of the lower limb concerned, with an IPS \< 0.8 or \> 1.3 * Patient with post-thrombotic obstructive syndrome at the popliteal and/or femoral and/or iliac stage on the ipsilateral lower limb * Patient with primary or post-thrombotic axial deep venous reflux on the ipsilateral lower limb * Suspicion of non-post-thrombotic iliac compression on echo-doppler * Contraindication to the planned treatment technique * Patient whose geographical distance is not compatible with the follow-up of the study * Pregnant or breastfeeding women * Patient linguistically or psychologically unable to understand the information given, to give informed consent or to answer the study questionnaires. * Protected patients: Adults under guardianship, or other legal protection; Hospitalized without consent.
๐Ÿ’Š

What it tests

  • EVLA 1940 nm
  • EVLA 1470 nm
๐Ÿ“

Where

1 site
Clinique Pasteur
Toulouse, France
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy